Safety and Immunogenicity of the Malaria Vaccine Candidate MSP3 Long Synthetic Peptide in 12–24 Months-Old Burkinabe Children
Sodiomon B. Sirima, Alfred B. Tiono, Alphonse Ouédraogo et al. · 2009
Read Safety and Immunogenicity of the Malaria Vaccine Candidate MSP3 Long Synthetic Peptide in 12–24 Months-Old Burkinabe Children by Sodiomon B. Sirima, Alfred B. Tiono, Alphonse Ouédraogo et al. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0007549.txt.
Description
Sodiomon Sirima and colleagues published a clinical trial report in PLOS ONE in 2009 on a malaria vaccine candidate called MSP3. MSP3 is a protein on the surface of the malaria parasite's blood stage. An earlier trial in European adults showed the vaccine raised antibodies that kill parasites in the lab. The new trial moved to the group that needs protection most: children aged twelve to twenty-four months in Burkina Faso.
The trial checked safety and immune response in those young children. A vaccine meant for toddlers in malaria regions must clear this bar before wider testing. Favorable results move the candidate one step closer to the field. Malaria kills mainly small children, so a vaccine proven gentle and active in them is the real goal. The study is one careful rung on that ladder.
Catalog record
| CREATOR | Sodiomon B. Sirima, Alfred B. Tiono, Alphonse Ouédraogo et al. |
|---|---|
| YEAR | 2009 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| LICENSE | Creative Commons Attribution License |
| RIGHTS | CC BY |
| SOURCE | PLOS ONE |
Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0007549